Healthtech startup Mykare has successfully secured an additional $1 million in a bridge funding round, bringing its total raised capital to $3.2 million. The investment was led by Andrew Parker and Alfredo Vaamonde, co-founders of the US-based healthtech company Papa.com, alongside a Middle-Eastern family office. This new capital injection is set to fuel the company's mission of making quality healthcare more affordable and accessible through its extensive network of hospitals.
Strategic Funding for AI and Expansion
Mykare plans to strategically deploy the fresh funds to enhance its proprietary artificial intelligence capabilities and accelerate its product development timeline. This investment will also be crucial in supporting the company's expansion strategy, allowing it to deepen its presence in existing international markets. The funding underscores a strong belief in Mykare's technology-driven approach to solving healthcare challenges.
The round's leadership from prominent figures in the US healthtech scene, combined with participation from a Middle-Eastern family office, signals significant international confidence. This follows a $2.2 million seed round in 2023 from investors including OnDeck ODX and Avaana Seed. The continued support from diverse investors highlights the global appeal of Mykare's innovative business model.
Innovating Patient Care with an AI-Native OS
At the core of its strategy, Mykare is developing an AI-native healthcare operating system designed to automate the entire patient journey. This system aims to help clinics and hospitals grow by streamlining processes from initial patient acquisition and appointment booking to feedback collection and retention. The platform is built to create a seamless and efficient experience for both patients and providers.
The startup's sophisticated AI agents can identify patient intent, manage incoming calls through advanced voice AI, and automatically update CRM records. This level of automation significantly reduces the administrative burden on healthcare facilities. By handling routine tasks, the system allows clinical staff to focus more on delivering high-quality patient care.
Currently, Mykare's AI agents are embedded in 30 to 35 larger healthcare facilities, with another 45 clinics already signed up for implementation. Co-founder Senu Sam confirmed the company's ambitious goal to expand its reach to 100 clinics soon. This rapid adoption rate demonstrates a clear market demand for its AI-powered solutions in the healthcare sector.
Global Reach and Market Context
Founded in 2022 by Senu Sam, Rahmatulla TM, and Joash Philipose, the company has quickly established a global network. Its services span the United States, the United Kingdom, the Middle East, and India, with a strong presence in major Indian metro cities. The startup reports a waiting list of over 20 hospitals and healthcare providers eager to join its network.
Mykare has already forged significant partnerships, including collaborations with a large oncology clinic chain in the US and a major dental chain in the UK. The company is also in advanced discussions with one of the largest dental chains in Qatar to further solidify its footprint in the Middle East. These alliances are key to its strategy of building a comprehensive international provider network.
This fundraise comes as India's healthtech ecosystem is rapidly evolving, moving towards AI-powered preventive care and integrated wellness platforms. The sector is projected to become a $37 billion opportunity by 2030, attracting notable investor interest. Mykare's focus on AI and automation positions it perfectly within this growing and dynamic market.
In conclusion, Mykare's latest funding round is a testament to the growing confidence in AI-driven solutions that enhance healthcare efficiency and patient access. With this new capital, the company is well-equipped to advance its technological platform and expand its global network. This strategic move positions Mykare to play a significant role in the ongoing transformation of the international healthtech industry.